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Abstract Upper respiratory tract infection (URTI) is an
acute infection which involves the upper respiratory tract:
nose, sinuses, tonsils and pharynx. URT infections are
caused mainly by pathogenic bacteria like Streptococcus
pneumoniae, Haemophilus influenzae and Staphylococcus
aureus. Conventionally, b-lactam antibiotics are used to
treat URT infections. Penicillin binding proteins (PBPs)
catalyze the cell wall synthesis in bacteria. b-Lactam
antibiotics like Penicillin, Cephalosporins, Carbapenems
and Monobactams inhibit bacterial cell wall synthesis by
binding with PBPs. Pathogenic bacteria have efficiently
evolved to resist these b-lactam antibiotics. New genera-
tion antibiotics are capable of inhibiting the action of PBP
due to its new and peculiar structure. New generation
antibiotics and Penicillin derivatives are selected in this
study and virtually compared on the basis of interaction
studies. 3-Dimensional (3D) interaction studies between
Lactivicin, Cefuroxime, Cefadroxil, Ceftaroline, Ceftobi-
prole and Penicillin derivatives with PBPs of the above-
mentioned bacteria are carried out. The aim of this study
was to suggest a potent new generation molecule for fur-
ther modification to increase the efficacy of the drug for the
URTI.
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Introduction
The respiratory tract is a frequent site of infection because it
comes in direct contact with the physical environment and is
exposed to airborne microorganisms. Worldwide, approxi-
mately 4 million children under 5 years of age die each year
from respiratory tract infections (RTIs) (Garenne et al.
1992). It is estimated that throughout the world 1.9 million
children\5 years old died from acute respiratory infection
in 2001, 70 % of them in Africa and South East Asia
(Williams et al. 2001). Nasopharyngitis, pharyngitis, ton-
sillitis and otitis media are common upper respiratory tract
(URT) infections which constitute 87.5 % of the total epi-
sodes of respiratory infections. URT infections can be
caused by a variety of bacteria like Chlamydia pneumoniae,
Mycoplasma pneumoniae, Streptococcus pyogenes, Strep-
tococcus pneumoniae, Bordetella pertussis, Staphylococcus
aureus, Escherichia coli and Haemophilus influenzae (Peter
et al. 1985). The majority of URT infections are caused by
only three species S. pneumoniae, S. aureus (Gram-positive
bacteria) and H. influenzae (Gram-negative bacteria). The
treatments of these three bacterial infections have been more
complicated by the emergence and spread of multi-drug
resistant strains (Doern et al. 1988, 1997). Two mechanisms
have been reported to be responsible for antibiotic resis-
tance: structural modification in Penicillin binding protein
(PBP) targets and production of b-lactamase, first identified
in 1972 (Williams and Moosdeen 1986; Reid et al. 1987;
Jorgensen 1992). PBPs are the membrane bound enzymes
which catalyze the steps involved in bacterial cell wall
biosynthesis and are the target enzymes of b-lactam antibi-
otics (Ghuysen 1991; Goffin and Ghuysen 1998; Macheb-
oeuf et al. 2006; Sauvage et al. 2008). Peptidoglycan is the
major component of bacterial cell wall synthesized by PBPs.
Every bacterial species has more than two PBPs.
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S. pneumoniae, the major human pathogen causing URT
infections is responsible for over 1.6 million deaths every
year (Lynch and Zhanel 2005). It has six PBPs, PBP1a,
PBP1b, PBP2a, PBP2b, PBP2x and PBP3, which are highly
conserved. Penicillin resistance in S. pneumoniae has been
reported in many countries. The mechanism of Penicillin
resistance is due to the modification of active site motif in
PBPs of S. pneumoniae. Penicillins and extended spectrum
Cephalosporins have high level of resistance to PBP1a,
PBP2x and PBP2b of S. pneumoniae (Sheldon and Mason
1998). S. aureus is a potent pathogen that can cause respi-
ratory tract infections (Ragle et al. 2010). It has PBP1b,
PBP2a and PBP3. The resistance of S. aureus to Penicillin
was identified in 1940 and 1965, but recently it has become a
major threat to public health concern (Metan et al. 2005),
alteration in PBP2a encoded gene decreases the affinity of
most b-lactam antibiotics. H. influenzae is a common and
exclusively human commensal of the nasopharynx. H. in-
fluenzae colonizes in the nasal cavity of approximately 80 %
of the human population. H. influenzae has PBP4 and PBP5
which are low molecular weight proteins. The treatment of
H. influenzae infections has been more complicated by the
emergence and spread of multi-drug resistant strains (Doern
et al. 1988, 1997). Several computational investigations
have been done on b-lactam antibiotics and PBPs. Yoshida
et al. reported the crystal structures of PBP3 in methicillin-
resistant S. aureus (MRSA) and nature of its interactions
with Cefotaxime. The study explains in detail about the
hydrophobic and hydrogen bond interaction of Cefotaxime
with the active sites of the PBP3 and PBP2 of S. aureus.
Experimentally they proved it with nanoelectrospray mass
spectrometry and ultracentrifugation to measure its sensi-
tivity to different types of Penicillin derivatives (Yoshida
et al. 2012). Samo Turk et al. study mainly focused to dis-
cover non-covalent inhibitor for PBP2x and PBP2a experi-
mentally and computationally. The study reported the
minimum inhibitory concentration of non-covalent inhibitor
against several Gram-positive bacterial strains, including
MRSA and analyzed the binding affinity of inhibitor with
PBP2a and PBP2x (Turk et al. 2011). Another computa-
tional study investigated the interaction of Carbenicillin,
Ceftazidime and Cefotaxime with binding site of PBP1b and
PBP3 (Sainsbury et al. 2011). Sainsbury et al. reported the
crystal structures of apo-PBP and complexes with Ceftazi-
dime and Carbenicillin and investigated the similarities and
differences between these structures. Fumihiro Kawai et al.
determined the high-resolution apo crystal structures of two-
low molecular weight PBPs, PBP4 and PBP5 from H. in-
fluenzae. They demonstrated the binding affinity of designed
b-lactam antibiotics and Amoxicillin with PBP4 and PBP5
(Kawai et al. 2010). Though Penicillin derivatives and
Cephalosporins have been used for bacterial infections over
a period of time, many bacterial pathogens have become
resistant to these antibiotics. One major mode of resistance is
by the alternation of PBPs resulting in low affinity to b-
lactam antibiotics. Researchers have explored the mecha-
nism of resistance to b-lactam antibiotics using only a few
Penicillin derivatives or Cephalosporins (Sainsbury et al.
2011; Turk et al. 2011; Yoshida et al. 2012). This prompted
us to investigate in detail using a wide spectrum of b-lactam
antibiotics (both Penicillin derivatives and Cephalosporins).
Our results indicate that of 19 b-lactam antibiotics, Cefto-
biprole and Ceftaroline might have better affinity to PBPs
and hence it may be effective in the treatment of URT
bacterial infections. Our results are also comparable to
previous experimental findings (Hebeisen et al. 2001; Sader
et al. 2005; Jones et al. 2005; Kosowska et al. 2005; Davies
et al. 2006; Citron and Goldstein 2008; Estrada et al. 2008;
Henry et al. 2010; Kosowska et al. 2010; Mosian et al. 2010;
Dauner et al. 2010) and the findings of our research might
provide clues as to how Ceftobiprole and Ceftaroline exert
their inhibitory action on bacterial pathogens.
Methods
Preparation of macromolecular and small molecular
models
PBP was thought to be essential for the synthesis of bacterial
cell wall. All types of the PBPs (PBP1a, PBP1b, PBP2a,
PBP2b, PBP2x, PBP3, PBP4, PBP5 and PBP6) were selected
for this study. 3-Dimensional (3D) structures of the PBPs
were obtained from Protein Data Bank (PDB) (Berman et al.
2000). 3D structures of PBPs were visualized through Py-
MOL viewer (Lill and Danielson 2010). Co-crystallized
ligands were identified and removed from the target proteins
then water molecules removed and H atoms were added to
the structure and minimizations were performed using Swiss
pdb viewer (Guex and Peitsch 1997). The 3D coordinates of
the Penicillin derivatives and Cephalosporins were obtained
from NCBI PubChem Compound database (Li et al. 2010)
and constructed using chemsketch (Li et al. 2004). Hydrogen
atoms were added to all the structures and gasteiger atomic
partial charges were computed. A geometry optimization of
all the compounds was performed using chimera (Pettersen
et al. 2004) for flexible conformations of the compounds
during the docking.
PDB ID of every PBP was depicted in Table 1 and two-
dimensional structures of Penicillin derivatives and Ceph-
alosporins are shown in Fig. 1.
Active site identification
The catalytic binding site was believed to be a small
region, a cleft or pocket, where lead molecules can bind to
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stimulate the target protein and produce the desirable
effect. Thus, recognizing the catalytic binding site residues
in the protein structure was of high importance in com-
puter-aided drug designing. Identification of accurate cat-
alytic binding site was difficult because the target proteins
were capable of undergoing conformational changes (Liao
and Andrews 2007). Qsite finder (Laurie and Jackson 2005)
recognizes the possible ligand binding sites using the van
der Waal’s probes and interaction energy. In the present
study, Qsite finder was employed for locating the active
sites in PBP1a, PBP1b, PBP2a, PBP2b, PBP2x, PBP3,
PBP4, PBP5 and PBP6 proteins.
Virtual screening of b-lactam antibiotics
iGEMDOCK (A Generic Evolutionary Method for
molecular DOCKing) automated docking program (Yang
and Chen 2004). iGEMDOCK integrated the structure-
based virtual screening, molecular docking, post screening
analysis and visualization steps. We selected all types of
PBPs (PBP1a, PBP1b, PBP2a, PBP2b, PBP2x, PBP3,
PBP4, PBP5 and PBP6) to carry out the structure-based
virtual screening study of penicillin derivatives and
Cephalosporins. The 3D coordinates of each therapeutic
target protein and ligand molecules were implemented
through the GEMDOCK graphical environment interface.
Before docking, the output path was set. GEMDOCK
default parameters included the population size
(n = 200), generation (g = 70) and number of solutions
(s = 10) to compute the probable ligand binding mecha-
nism for each target protein. Then the docking run was
started using GEMDOCK scoring function. After docking,
the individual binding pose of each ligand was observed
and their binding affinity with the target proteins was
analyzed. In the post docking screening the best binding
pose and total energy of each ligand was analyzed. The
details of best binding pose and total energy values were
saved in output folder. Protein–ligand binding site was
analyzed and visualized using PyMOL (Lill and Daniel-
son 2010).
Docking
The automated docking studies were carried out using
Auto-Dock version 4.0 (Morris et al. 2009). 3D structure of
each PBPs were implemented through the graphical user
interface AUTODOCKTOOLS (ADT 1.4.6). The graphical
user interface AUTODOCKTOOLS was performed to set
up the enzymes: all hydrogens were added, Kollman Uni-
ted Atoms charges loaded and non-polar hydrogens were
merged to carbon atoms. The initial parameters and van der
Waals well depth of 0.100 kcal/mol for macromolecules,
generated PDBQT files were saved. The 3D structures of
ligand molecules were constructed, optimized, and con-
verted into Mol2 file format with the help of the chimera.
The charges of the non-polar hydrogen atoms are assigned
to the atom to which the hydrogen is attached. The
resulting files were saved as PDBQT files. The drug
binding site for the ligands on PBP1a, PBP1b, PBP2a,
PBP2b, PBP2x, PBP3, PBP4, PBP5 and PBP6 were iden-
tified using Qsite finder online server. The grid point was
set at the ligand binding site in each one of the obtained
Table 1 Active site residues of PBPs
PBPs PDB ID Name of the organism Active site residues
PBP1a 2C6W Streptococcus pneumoniae Ala270, Tyr271, Asp273, Asn274, Trp311, Asn315, Leu345, Gly346, Ala347,
Arg348, His349, Hln350, Ser351
PBP1b 2Y2Q Staphylococcus aureus Asp337, Phe341, Thr342, Ala345, Glu346, Glu349, Tyr443, Gln447, Asn448,
Asn449, Phe452, Asp453, Glu540
PBP2a 1VQQ Staphylococcus aureus Ser403, Lys406, Arg445, Tyr446, Glu447, Ile459, Glu460, Ser403, Ser462,
Asp463, Asn464
PBP2b 2WAE Streptococcus pneumoniae Thr55, Thr56, Ser57, Ser81, Gln180, Ala183, Val184, Gly185, Ala188, Thr189,
Gly190, Thr191, Ser218, Ser258, Leu259, Asn260, Asp261, Arg 262, Arg280
PBP2x 1PYY Streptococcus pneumoniae Lys420,Val423, Pro424, Thr425, Arg426, Arg463, Glu476, Glu497, Ile498,
Val499, Gly500, Ala650, Arg654, Pro660, Ile661, Val662, Gly664
PBP3 3OC2 Streptococcus pneumoniae Ala162, His163, Gly166, Phe167, Arg175, Glu176, Gly177, Leu180, Tyr268,
Pro278, Met281, Arg282, Asn283, Met286, Ile287, Phe383, Pro384, Gly385,
Glu386, Arg387
PBP4 1TVF Staphylococcus aureus Gln133, Val136, Ser137, Asn138, Ser139, Phe225, Phe225, Thr226, Lys227,
Gln228, Tyr239, Thr240, Phe241, Asn242, Leu245, Leu258, Lys259, Thr260
PBP5 3A3J Haemophilus influenzae Val75, Val77, Leu79, Lys80, Asn86, Asn121, Asp193, Leu194, Leu194, Pro195,
Glu196, Glu197, Ile200
PBP6 3ITB Escherichia coli Ser40, Ile103, Ile104, Gln105, Ser106, Pro192, Asn193, Arg194, Asn195,
Met208, Lys209, Thr210, Gly211, Thr212
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PDB structures. AUTODOCK 4.0 was performed for all
docking calculations. The AUTODOCKTOOLS was used
to generate the grid parameter files and docking parameter
files. The docking parameters were also used to calculate
docking scores for b-lactam antibiotics and Penicillin
derivatives. Protein–ligand docking calculations were car-
ried out on PBPs. Lamarckian genetic algorithm (Morris
et al. 1998) was used to generate possible protein–ligand
binding conformations.
ADME screening
The molinspiration (Jarrahpour et al. 2011) server was used
to predict the ADME properties of the antibiotics. It
Fig. 1 3-Dimensional structures of Penicillin derivatives and Ceph-
alosporins: a Amoxicillin, b Ampicillin, c Azlocillin, d Carbenicillin,
e Cefuroxime, f Cloxacillin, g Dicloxacillin, h Flucloxacillin, i Mez-
locillin, j Piperacillin, k Methicillin, l Nafcillin, m Oxacillin,
n Penicillin G, o Ticarcillin, p Ceftobiprole, q Ceftaroline, r Cefa-
droxil and s Lactivicin (The highlighted boxes indicate the non-
essential components in p Ceftobiprole and q Ceftaroline
respectively)
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predicted both physiochemical and pharmacological prop-
erties. Smiles (Simplified Molecule Input Line Entry
Specification) of the antibiotics was submitted. It predicted
the properties of the drug such as molecular volume,
number of hydrogen bond donors and acceptors, LogP and
rotatable bonds. It provided high-speed molecular proper-
ties calculated and drug likeness for a given compound.
The acceptability of the analogs is evaluated based on
Lipinski’s rule of 5 (Lipinski et al. 2006), which is essential
for structure-based drug design.
Results and discussion
The 3D structures of PBP1a, PBP1b, PBP2a, PBP2b,
PBP2x, PBP3, PBP4, PBP5 and PBP6 are analyzed and 19
b-lactam antibiotics are optimized to have minimal
potential energy using chimera and then the virtual
screening study is carried out for ligand molecules. From
the virtual screening analysis, we list binding mode of
Penicillin derivatives and Cephalosporins based on total
energy (Table 2). The best binding poses for each ligand
molecule into each target protein are determined and the
one having lowest binding energy among the different
poses generated. The lower energy scores represent better
protein–ligand binding affinity compared to higher energy
values. Among the 19 ligands, Cephalosporins are found to
have lower binding energy value than the Penicillin
derivatives. Especially the fifth generation Cephalosporins,
Ceftaroline and Ceftobiprole has least binding energy
value. Ceftobiprole shows best binding pose with PBP1b,
PBP2a, PBP2b and PBP2x (total energy value for
PBP1b = -110.7 kcal/mol, PBP2a = -108.2 kcal/mol,
PBP2b = -110.4 kcal/mol, PBP2x = -116 kcal/mol).
The Ceftaroline shows best binding conformation with
PBP3, PBP4, PBP5 and PBP6 (total energy for PBP3 =
-114 kcal/mol, PBP4 = -104.8 kcal/mol, PBP5 =
-131.2 kcal/mol and PBP6 = -118.0 kcal/mol). On
comparing the binding mode of Penicillin derivative, Az-
locillin shows higher binding affinity with PBP1a (total
energy value = -122.1 kcal/mol). These compounds have
more stable ligand–receptor complex amongst other com-
pounds. We further analyzed the docked conformation for
finding the binding mode of fifth generations Cephalo-
sporins, Ceftaroline and Ceftobiprole into selected target
proteins to validate the position obtained likely to represent
reasonable binding modes or conformations.
Docking of Ceftobiprole into PBPs
Docking simulation of Ceftobiprole is performed for
PBP1a, PBP1b, PBP2a, PBP2b, PBP2x, PBP3, PBP4,
PBP5 and PBP6. From the docking result, we identified
that Ceftobiprole has best binding affinity with the PBP2x
of S. aureus. Docking of Ceftobiprole results in the for-
mation of more than five hydrogen bonds with PBP1b,
Table 2 Virtual screening results of b-lactam antibiotics by iGEMDOCK
S. no #Ligand PBP-1A PBP-1B PBP-2A PBP-2B PBP-2X PBP-3 PBP-4 PBP-5 PBP-6
1 Amoxicillin -121.1 -103.7 -89.8 -88.2 -84.1 -94.5 -67.6 -98.7 -79.9
2 Ampicillin -89.3 -69.3 -87.3 -76.1 -82.1 -86.0 -64.8 -94.4 -84.4
3 Azlocillin -122.1 -83.3 -99.8 -93.9 -84.4 -100.4 -72.9 -91.4 -85.0
4 Carbenicillin -86.6 -74.9 -91.8 -84.7 -97.6 -98.2 -75.5 -107.6 -90.4
5 Cefadroxil -107.5 -87.4 -90.1 -100.3 -101.7 -112.9 -72.3 -88.6 -83.4
6 Ceftobiprole -104.6 -110.7 -108.2 -110.4 2116.0 -113.0 -83.2 -113.0 -102.0
7 Ceftaroline -104.3 -97.1 -79.4 -97.0 -104.4 2114.1 2104.8 2131.2 2118.0
8 Cefuroxime -103.4 -104.0 -94.6 -110.3 -94.3 -86.1 -78.2 -91.0 -80.0
9 Cloxacillin -91.4 -90.9 -83.3 -89.4 -82.0 -89.4 -69.0 -94.3 -82.0
10 Dicloxacillin -95.9 -83.9 -85.7 -82.6 -99.1 -97.1 -62.7 -85.2 -84.0
11 Flucloxacillin -89.6 -75.4 -96.6 -88.9 -74.9 -89.8 -62.1 -90.8 -82.1
12 Lactivicin -91.1 -95.9 -87.1 -90.9 -95.8 -95.3 -65.6 -98.1 -89.0
13 Methicillin -95.5 -102.1 -102.0 -97.0 -92.3 -109.6 -74.9 -93.5 -94.0
14 Mezlocillin -88.6 -101.9 -102.1 -92.9 -97.4 -105.0 -72.4 -112.1 -97.1
15 Nafcillin -89.3 -100.8 -77.3 -82.0 -111.4 -101.5 -67.1 -97.8 -84.3
16 Oxacillin -101.6 -88.5 -94.2 -86.9 -78.1 -90.3 -67.5 -97.4 -87.1
17 Penicillin G -84.3 -74.4 -77.3 -79.3 -83.1 -89.5 -66.2 -81.6 -72.2
18 Piperacillin -89.2 -86.4 -81.3 -97.5 -97.1 -103.7 -73.4 -99.8 -88.0
19 Ticarcillin -99.8 -79.1 -81.6 -85 -80.9 -86.3 -64.7 -95.2 -92.0
The values in bold font indicate best binding energies
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PBP2a, PBP2b and PBP2x (Fig. 2). Amino acid residues
Gln582, Glu540, Lys603 and Gln601 are involved in
interaction with PBP1b; in PBP2a, the interacting amino
acids are Ala642, Thr600, Tyr519, Ser403, Ser462, Asn464
and Lys406. In PBP2b, Asn260, Tyr257, Thr191 and
Gln180 are involved in the interaction with Ceftobiprole. In
close assessment of this binding mode, binding docking
energies are calculated for PBP1b, PBP2a, PBP2b, and
PBP2x (Table 3). In PBP2x, the amino acid residues
Gln621, Lys496, Gln495, Ser481 and Thr623 interact with
Ceftobiprole (Table 4). Davies et al. (2006) report that
Ceftobiprole itself inhibits PBP1a, PBP2b and PBP2x,
which are responsible for Penicillin resistance in S.
pneumoniae. Our results are similar to the findings of
Davies et al. Ceftobiprole, a fifth generation Cephalosporin
in phase 3 clinical trials, exhibits a broad spectrum of
activities against many clinically important Gram-positive
and Gram-negative pathogens, such as S. pneumoniae, H.
influenzae, and S. aureus (Hebeisen et al. 2001; Jones et al.
2002; Kosowska et al. 2005; Zbinden et al. 2002). Docking
analysis of Ceftobiprole shows best results against S.
pneumoniae and S. aureus. Our results are similar to pre-
vious studies (Hebeisen et al. 2001; Jones et al. 2002;
Kosowska et al. 2005). Lovering et al. (2012) report that
the affinity of Ceftobiprole to PBP2a of MRSA is high.
Henry et al. (2010)
Fig. 2 Docking results of Ceftobiprole against PBP1b, PBP2a,
PBP2b and PBP2x. a Binding mode of Ceftobiprole in PBP1b. b A
close-up view of the binding site of Ceftobiprole in PBP2a.
c Ceftobiprole interaction with PBP2b. d Binding mode of
Ceftobiprole with PBP2x. Ligand atoms are colored by its type.
The interacted amino acids residues, hydrogen bond networks in the
binding pocket and the distance (in A˚ units) of bonds are all shown
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report that PBP5 has less sensitivity to Ceftobiprole
than PBP2a. Another study reveals that Ceftobiprole is a
novel broad-spectrum antibiotic that inhibits PBP2a and
PBP2x, which are responsible for the resistance in
S. pneumoniae and S. aureus, respectively (Dauner et al.
2010). Though many reports on the inhibitory activity of
Ceftobiprole for specific PBPs are available in literature,
none of the studies have focused on the binding pattern of
Ceftobiprole to all type of PBPs. Our study reveals the
binding pattern of Ceftobiprole with all type of PBPs. The
possible binding mode of Ceftobiprole in the PBP1b,
PBP2a, PBP2b, PBP2x binding site and corresponding 2D
interaction models along with hydrogen bonds and bond
distance are shown in Fig. 2.
Docking of Ceftaroline into PBPs
Ceftaroline is a antibiotic of the Cephalosporin type among
the majority of currently available b-lactam antibiotics.
Cephalosporins are used for effective treatment of bacterial
respiratory tract infections. In our results on the binding
conformation modes of Penicillin derivatives and Cepha-
losporins with PBPs, Ceftaroline shows higher affinity with
the PBP3, PBP4, PBP5 and PBP6 than the other PBPs. In
examining the interaction and position of the Ceftaroline in
PBP3, PBP4, PBP5 and PBP6 active site predicted by our
docking procedure, it is observed that multiple hydrogen
Table 3 AutoDock estimated docked energies of Ceftobiprole and
Ceftaroline




1 PBP1a -5.1 -5.2
2 PBP1b -6.76 -4.12
3 PBP2a -6.12 -3.43
4 PBP2b -7.04 -5.1
5 PBP2x -7.32 -5.3
6 PBP3 -6.1 -7.42
7 PBP4 -4.34 -5.65
8 PBP5 -6.21 -9.2
9 PBP6 -5.3 -8.3
Table 4 H-bond interactions and bond length obtained for Ceftobi-
prole with PBP1b, PBP2a, PBP2b and PBP2x
Protein–ligand complex H-bond interactions Bond length (A˚)




























Table 5 H-bond interactions and bond length obtained for Ceftaro-
line with PBP3, PBP4, PBP5 and PBP6
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bonds are formed (Table 5). In addition, the amino acid
residues Arg54, Glu121 and Tyr124 of PBP3 are involved
in van der Waals’ interactions. In PBP4, only one amino
acid residue Asn260 is involved in interaction with Cef-
taroline. Binding of Ceftaroline to PBP5 and PBP6
involves more than six hydrogen bonds. The binding
affinity of Ceftaroline for MRSA PBP2a, methicillin-sus-
ceptible S. aureus (MSSA) PBPs 1 to 3, and S. pneumoniae
PBP2x/2a/2b correlates well with its low MICs and bac-
tericidal activity against these resistant organisms (Kos-
owska et al. 2010; Moisan et al. 2010). Citron et al. report
the effects of Ceftaroline activity against Gram-positive
and Gram-negative pathogens, including MSSA, MRSA,
E. faecalis, S. pyogenes, S. pneumoniae, H. influenzae, M.
catarrhalis, K. pneumonia, E. coli, P. aeruginosa, and A.
baumannii (Citron and Goldstein 2008; Jones et al. 2005).
Other studies reveal that Ceftaroline has potent activity
against MRSA and S. pneumoniae. The Gram-negative
spectrum of Ceftaroline is similar to that of other broad-
spectrum Cephalosporins (Estrada et al. 2008; Moisan et al.
2010; Kosowska et al. 2010). Morrissey et al. report that
the Ceftaroline has excellent activity against MRSA and
Penicillin-resistant S. pneumoniae. Furthermore, Ceftaro-
line maintains good activity against H. inlfuenzae (Sader
et al. 2005; Mushtaq et al. 2007; Morrissey et al. 2009).
Our results are consistent with the previously studied ones
(Kosowska et al. 2010; Moisan et al. 2010; Citron and
Goldstein 2008; Jones et al. 2005; Estrada et al. 2008;
Kosowska et al. 2010; Sader et al. 2005; Mushtaq et al.
2007; Morrissey et al. 2009). Although many studies have
been reported the inhibitory action of Ceftaroline to spe-
cific PBPs, no studies have been done for the binding
pattern of Ceftaroline with all type of PBPs. Our results
clearly explain the binding pattern of Ceftaroline with all
type of PBPs. The binding energy calculated by AutoDock
for Ceftaroline–PBP complexes is shown in Table 3. The
best possible binding mode of Ceftaroline in PBP4, PBP5
and PBP6 and their corresponding 2D interaction models
are displayed in Fig. 3.
ADME screening
For each of the Penicillin derivatives and Cephalosporins,
we analyzed for a number of physiochemical properties
Fig. 3 Docked complex of Ceftaroline–PBP3, PBP4, PBP5 and
PBP6. a A close-up view of the predicted binding site for Ceftaroline
in PBP3. b Binding mode of Ceftaroline with PBP4. c Ceftaroline
binding site in PBP5. (3D) Interaction of Ceftaroline with PBP6.
Ligand atoms are colored by its type. The interacted amino acids
residues, hydrogen bond networks in the binding pocket and the
distance (in A˚ units) of bonds are all shown
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and pharmaceutically relevant properties, such as molecu-
lar weight, H-bond donors, H-bond acceptors, logP (octa-
nol/water), and their position according to Lipinski’s rule
of 5 (Table 6). Lipinski’s rule of 5 is a rule of thumb to
predict drug likeness, or determine if a compound with a
certain biological or pharmacological activity has proper-
ties that would make it a likely orally active drug in
humans. The rule describes physiochemical properties
important for a drug’s pharmacokinetics in the human
body, including its ADME. The drug molecule shows poor
absorption and permeation when they have more than 5
hydrogen bond donors, molecular weight over 500, logP is
over 5 and more than 10 hydrogen bond acceptors. In this
study, of the 19 ligands, 16 structures showed possible
values for the properties analyzed and exhibited drug-like
characteristics based on Lipinski’s rule of 5. Methicillin
has more than 7 rotatable bonds. Rotatable bond more than
10 and molecular weight more than 500 can lead to
decreased permeability and oral bioavailability. But Cef-
tobiprole and Ceftaroline show molecular weight more
than 500. Hence to improve the action of these two drugs,
we have highlighted the non-essential regions (Fig. 1) that
may possibly be spliced to reduce the molecular mass.
However, the effectiveness of these low molecular mass
compounds has to be tested in both in vivo and in vitro.
Conclusion
In the present study, molecular docking studies were per-
formed to explore possible binding modes of Penicillin
derivatives and Cephalosporins into all types of PBPs,
PBP1a, PBP2b, PBP2x and PBP3 of S. pneumoniae,
PBP1b, PBP2a and PBP4 of S. aureus, PBP5 of H. influ-
enzae, as these organisms are most frequently found
pathogens in the URT. The molecular docking study
revealed that the Cephalosporins show higher affinity with
PBPs than the Penicillin derivatives. Especially the fifth
generation Cephalosporins, Ceftobiprole and Ceftaroline
show best results to all types of PBPs. The binding affinity
was evaluated by the binding free energies (DGb, Kcal/
mol) and hydrogen bonding. The compounds which
revealed the highest binding affinity are the ones with
lowest binding free energy. On comparing the binding
energy and the binding site residues, we found that all
compounds differ in their binding modes or binding site
residues for hydrogen bond formation. The conclusion
drawn from this virtual screening and docking result was
that the Ceftobiprole has highest binding affinity with the
PBP2x of S. pneumoniae. The Ceftaroline has maximum
number of interaction with PBP5 of H. influenzae. The
above results suggest that the Ceftobiprole and Ceftaroline
can be potent inhibitors for all types of PBPs. From ADME
screening of all the 19 compounds, 16 compounds satisfied
Lipinski’s rule of 5. Ceftobiprole and Ceftaroline show
molecular weight more than 500 which decreases their
permeability and bioavailability. These drugs can further
be modified to satisfy Lipinski’s rule of 5. Though, there
are a few reports on the in vitro analysis of Ceftobiprole
and Ceftaroline, there are no in silico studies that predict
the binding and active regions in these molecules. Our
study is probably the first such attempt and we infer that
our results will throw light for the future development of
more potent next generation antibiotics for the treatment of
upper respiratory infections and counter the emergence of
antibiotic resistant strains.
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Table 6 Molecular properties of Penicillin derivatives and Cepha-



















1 Amoxicillin 2.31 365.40 6 4 4
2 Ampicillin -2.00 349.40 5 3 4
3 Azlocillin 0.20 461.49 6 4 5
4 Carbenicillin 1.13 378.39 6 3 5
5 Cloxacillin 2.61 435.88 5 2 4
6 Dicloxacillin 2.90 470.32 5 2 3
7 Flucloxacillin 2.69 453.87 5 2 3
8 Methicillin 0.85 380.41 10 3 11
9 Mezlocillin 0.21 539.58 8 3 5
10 Nafcillin 3.21 414.47 5 2 5
11 Oxacillin 2.05 401.43 5 2 4
12 Penicillin G 1.5 334.39 4 2 4
13 Piperacillin 1.2 517.55 7 2 6
14 Ticarcillin 0.99 384.42 6 3 5
15 Ceftobiprole -1.68 564.16 11 7 4
16 Ceftaroline 2.43 699.03 16 5 2
17 Cefadroxil -1.22 377.10 7 5 3
18 Lactivicin -0.60 296.14 5 1 2
19 Cefuroxime -0.2 424.39 10 3 7
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